Advertisement

Impact of Drug Adherence in Clinical Trials

  • Michel Burnier
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

In randomized clinical trials assessing the efficacy or benefits of a new drug treatment or a new treatment strategy, it is generally assumed that patients follow strictly the recommendations on how and when to take their medications. Therefore, little attention is given to adherence and this latter is rarely measured adequately. When it is, data are often handled inappropriately. The purpose of this chapter is to discuss the problems of drug adherence in clinical trials and to review the multiple consequences that a low adherence might have such as failure to demonstrate efficacy, underestimation of the drug efficacy, underestimation of safety concerns, and increased study costs.

Keywords

Evidence based medicine Clinical trials Randomization Meta-analysis 

References

  1. 1.
    Masic I, Miokovic M, Muhamedagic B. Evidence based medicine—new approaches and challenges. Acta Inform Med. 2008;16(4):219–25.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58(4):573–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366(9502):2005–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Breckenridge A, Aronson JK, Blaschke TF, Hartman D, Peck CC, Vrijens B. Poor medication adherence in clinical trials: consequences and solutions. Nat Rev Drug Discov. 2017;16(3):149–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275–301.CrossRefPubMedGoogle Scholar
  7. 7.
    Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pullar T, Kumar S, Feely M. Compliance in clinical trials. Ann Rheum Dis. 1989;48(10):871–5.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci. 2007;334(4):248–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Investigators ET, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94.CrossRefGoogle Scholar
  12. 12.
    Czobor P, Skolnick P. The secrets of a successful clinical trial: compliance, compliance, and compliance. Mol Interv. 2011;11(2):107–10.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kubo Y, Sterling LR, Parfrey PS, et al. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial. Pharm Stat. 2015;14(4):368.CrossRefPubMedGoogle Scholar
  14. 14.
    Beaussier H, Boutouyrie P, Bobrie G, et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J Hypertens. 2015;33(12):2526–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30(8):1656–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Service of Nephrology and Hypertension, Department of MedicineCentre Hospitalier Universitaire Vaudois (CHUV), University HospitalLausanneSwitzerland

Personalised recommendations